ATH · ASX

Alterity Therapeutics Ltd. (ASX:ATH)

AU$0.0055

 -0.0015 (-21.429%)
ASX:Live
20/12/2024 03:57:20 PM
HALO Ords HALO Consensus Value GROWTH AUS Fakey Shakey - Short EMA 125 Breakup +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ATH Overview

ATH Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ATH

Website

Alterity Therapeutics Ltd.

Telephone

61.3.9349.4906

Address

Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000

Description

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

ATH Price Chart

Key Stats

Market Cap

AU$37.24M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$13,730.00

1 week

16.67%

1 month

133.33%

YTD

0%

1 year

0%

All time high

1.50

Key Fundamentals

EPS 3 yr Growth

-42.20%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

-68.60%

ROIC

-104.00%

Interest Coverage

N/A

Quick Ratio

3.50

Other Data

Shares on Issue (Fully Dilluted)

4776m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.02

ATH Announcements

Latest Announcements

Date Announcements

04 December 24

Alterity Announces Completion of Phase 2 Clinical Trial

×

Alterity Announces Completion of Phase 2 Clinical Trial

22 November 24

Chairman's Address 2024 Annual General Meeting

×

Chairman's Address 2024 Annual General Meeting

22 November 24

Presentation to Annual General Meeting

×

Presentation to Annual General Meeting

22 November 24

Results of Meeting

×

Results of Meeting

19 November 24

Change of Company Secretary

×

Change of Company Secretary

12 November 24

ATH Presentation Tracking MSA Progression at Intl Symposium

×

ATH Presentation Tracking MSA Progression at Intl Symposium

06 November 24

Alterity Announces Publication On ATH434 Mechanism of Action

×

Alterity Announces Publication On ATH434 Mechanism of Action

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

23 October 24

Notice of Annual General Meeting

×

Notice of Annual General Meeting

14 October 24

ATH to Participate in 2024 Maxim Healthcare Virtual Summit

×

ATH to Participate in 2024 Maxim Healthcare Virtual Summit

11 October 24

Alterity Presents Data Describing Neuroprotection of ATH434

×

Alterity Presents Data Describing Neuroprotection of ATH434

04 October 24

Change of Share Registry

×

Change of Share Registry

02 October 24

Alterity Data Presentations at MDS Congress Raises Profile

×

Alterity Data Presentations at MDS Congress Raises Profile

30 September 24

ATH Appoints Abby Macnish Niven as Chief Financial Officer

×

ATH Appoints Abby Macnish Niven as Chief Financial Officer

30 September 24

Alterity Therapeutics Filed Form 20-F and XBRL data with SEC

×

Alterity Therapeutics Filed Form 20-F and XBRL data with SEC

26 September 24

Annual Report 2024

×

Annual Report 2024

26 September 24

Corporate Governance Statement

×

Corporate Governance Statement

26 September 24

Appendix 4G

×

Appendix 4G

23 September 24

Alterity to Deliver Multiple Presentations at MDS Congress

×

Alterity to Deliver Multiple Presentations at MDS Congress

20 September 24

Change of Director's Interest Notice - BM / PM

×

Change of Director's Interest Notice - BM / PM

02 September 24

Notification of cessation of securities - ATH

×

Notification of cessation of securities - ATH

29 August 24

Appendix 4E Preliminary Final Report

×

Appendix 4E Preliminary Final Report

01 August 24

Notification of cessation of securities - ATH

×

Notification of cessation of securities - ATH

31 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 July 24

Alterity Therapeutics to Present at MST Financial Webinar

×

Alterity Therapeutics to Present at MST Financial Webinar

ATH Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.1 -7.5 8.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.5 4.5 37.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -39.7 -117.9 -86.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.8 -36.6 -71.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 2,406 2,428 3,649 Lock Lock Lock
Basic m Lock Lock Lock Lock 2,406 2,428 3,649 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 21 18 23 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.1 -88.6 -44.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -21 -18 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.8 10.4 -27.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -21 -19 -24 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.7 10.2 -27.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -17 -18 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -5 -4 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -13 -14 -19 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.1 -7.5 -38.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -20 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 16 0 9 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -12 -20 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.3 -61.3 37.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 35 16 13 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 41 27 19 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -35 -16 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 6 5 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 35 23 14 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 36 23 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.5 -35.5 -39.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -31.1 -50.5 -99.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -36.2 -60.5 -138.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -62.4 -63.2 -127.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -38.9 -47.2 -104.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -37.4 -68.6 -68.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 0.8 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -97.8 -68.2 -90.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 7.1 6.2 3.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 7.1 6.2 3.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.6 58.3 66.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -212.0 -457.2 -234.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -31.1 -50.5 -99.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -36.2 -60.5 -138.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -36.2 -60.5 -138.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 13,931.3 7,866.4 2,842.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -13,931.3 -7,866.4 -2,842.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.02%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ATH Shortsell

Frequently Asked Questions

The current share price of Alterity Therapeutics Ltd. (ATH:ASX) is AU$0.0055.
The 52-week high share price for Alterity Therapeutics Ltd. (ATH:ASX) is AU$0.01.
The 52-week low share price for Alterity Therapeutics Ltd. (ATH:ASX)? is AU$0.00.
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
Alterity Therapeutics Ltd. (ATH:ASX) has a franking level of 0.0%.
Alterity Therapeutics Ltd. (ATH:ASX) is classified in the Healthcare.
The current P/E ratio for Alterity Therapeutics Ltd. (ATH:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.